Hikma Pharmaceuticals

Hikma Pharmaceuticals

Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan in 1978. 

About Hikma Pharmaceuticals

Share price for Hikma Pharmaceuticals

LON: HIK Dividends

Historical Data

Latest Hikma Pharmaceuticals News

Hikma Pharmaceuticals reports strong 2024 results, with double-digit revenue growth, increased profits, and strategic acquisitions fueling optimism for 2025....
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities....
Hikma Pharmaceuticals PLC provides a trading update ahead of its Annual General Meeting. CEO Riad Mishlawi highlights strong growth and...

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 22.2% according to RBC Capital Markets.

[stock_market_widget type="chart" template="basic"...

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential downside of -12.8% according to Barclays.

[stock_market_widget type="chart" template="basic" color="green" assets="HIK.L"...

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential downside of -15.0% according to Barclays.

[stock_market_widget type="chart" template="basic" color="green" assets="HIK.L"...

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.